Focused On-demand Library for E3 ubiquitin-protein ligase RNF25

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96BH1

UPID:

RNF25_HUMAN

Alternative names:

RING finger protein 25; RING finger protein AO7

Alternative UPACC:

Q96BH1; A8K0D6; Q53HQ5; Q9H874

Background:

E3 ubiquitin-protein ligase RNF25, also known as RING finger protein 25, plays a pivotal role in the RNF14-RNF25 translation quality control pathway. This pathway activates when a ribosome stalls during translation, leading to the ubiquitination and degradation of translation factors on stalled ribosomes. RNF25 specifically catalyzes the ubiquitination of RPS27A, triggering RNF14 activation, and targets other ribosomal proteins for ubiquitination. Beyond its role in stalled ribosome response, RNF25 is involved in the ubiquitination of NKD2 and may enhance NF-kappa-B mediated transcription through RELA/p65 interaction.

Therapeutic significance:

Understanding the role of E3 ubiquitin-protein ligase RNF25 could open doors to potential therapeutic strategies.